Secondary Marketplace / Trade Private Companies / Buy and Sell BioAge Stock
BioAge BioAge Stock
$440.23MM
Series D Valuation, Feb 2024
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies similar to BioAge before its IPO, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

BioAge Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

BioAge Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/13/2024 Series D-1 $24.39MM $xx.xx $440.23MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
11,887,535
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
02/13/2024 Series D $170MM $xx.xx $440.23MM Amgen Ventures, Andreessen Horowitz, Cormorant Asset Management, Lilly Ventures, Longitude Capital, Orbimed Advisors, Osage University Partners, Pivotal Bioventure Partners, Ra Capital, Rtw Investments, Sands Capital, Sofinnova Investments, Sv Health Investors
Price per Share
$xx.xx
Shares Outstanding
49,713,403
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Andreessen Horowitz, Cormorant Asset Management, Lilly Ventures, Longitude Capital, Orbimed Advisors, Osage University Partners, Pivotal Bioventure Partners, Ra Capital, Rtw Investments, Sands Capital, Sofinnova Investments, Sv Health Investors
12/03/2020 Series C $95MM $xx.xx $270.18MM Aarp Foundation, Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Kaiser Foundation Hospitals, Pear Ventures, Phi-X Capital, Redpoint Ventures
Price per Share
$xx.xx
Shares Outstanding
16,076,886
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Aarp Foundation, Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Kaiser Foundation Hospitals, Pear Ventures, Phi-X Capital, Redpoint Ventures
01/24/2019 Series B $22.93MM $xx.xx $86.05MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Felicis Ventures, Khosla Ventures, Pear Ventures, Redpoint Ventures
Price per Share
$xx.xx
Shares Outstanding
7,455,241
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Felicis Ventures, Khosla Ventures, Pear Ventures, Redpoint Ventures
07/28/2017 Series A-2 $1.81MM $xx.xx $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$xx.xx
Shares Outstanding
2,948,071
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-3 $250,006.84 $xx.xx $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$xx.xx
Shares Outstanding
203,821
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-4 $54,998.51 $xx.xx $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$xx.xx
Shares Outstanding
27,643
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
07/28/2017 Series A-1 $11.82MM $xx.xx $43.84MM Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Price per Share
$xx.xx
Shares Outstanding
4,753,466
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ame Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Pear Ventures
Company Details
BioAge develops a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging by using its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging.
Founded
2015
Post-Money Valuation 3
$440.23MM
Total Funding
$1.42B
LFR Price per Share
$xx.xx
Last Funding Share Class
Series D
BioAge Stock FAQs
To buy and sell BioAge stock
Can you buy BioAge stock?
You can no longer buy BioAge stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy BioAge stock?
You can no longer buy BioAge stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell BioAge stock?
You can no longer sell stock of BioAge on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell BioAge stock?
You can no longer sell stock of BioAge on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about BioAge stock
Is BioAge a public company?
BioAge is now a public company traded on NASDAQ with ticker BIOA.
What is BioAge’s stock price?
The stock price of BioAge is not currently available.
What is BioAge’s stock ticker symbol?
The ticker symbol of BioAge is BIOA.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

BioAge Investors Also Invested in These Private Companies

Pivotal Bioventure Partners
Lilly Ventures
Springboard Enterprises
Sv Health Investors
Pear Ventures
Aarp Foundation
Kaiser Foundation Hospitals
Phi-X Capital

Leadership & Board

Leadership

Kristen Fortney Ph.D
Co-Founder & Chief Executive Officer
Eric Morgen MD
Co-Founder & Chief Operating Officer
BJ Sullivan Ph.D
Chief Strategy Officer
Ann Neale
Chief Development Officer
Peng Leong Ph.D
Chief Business Officer & Therapeutic Area Head, Brain Aging
Paul Rubin MD
Chief Medical Officer & Executive Vice President of Research
Dov Goldstein MD
Chief Financial Officer

Board

James Healy Ph.D
Sofinnova Investments
Vijay Pande Ph.D
Andreessen Horowitz

BioAge News and Media Highlights

RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc

On September 27, 2024, RA Capital Management, L.P., a prominent investment firm, made a significant move in the biopharmaceutical sector by acquiring 2,210,589 shares of Bioage Labs Inc (NASDAQ:BIOA). This transaction, valued at $21 per share, marks a new holding for the firm, reflecting a strategic investment in the healthcare industry. The acquisition not only diversifies RA Capital's portfolio but also underscores its commitment to investing in innovative companies tackling major healthcare challenges.

BioAge Labs Readies $135 Million U.S. IPO To Advance Obesity Treatments

BioAge Labs (BIOA) has filed proposed terms to raise $135 million from the sale of its common stock in an IPO, according to an amended SEC registration statement. The company is a clinical-stage biopharma developing treatments for various metabolic diseases. Early trial results in combination with existing approved drugs have been encouraging and the company is well-capitalized and backed by a large syndicate of well-known venture capital, private equity and strategic investors.

GLP-1 enthusiasm pushes BioAge Labs into new age with $170M series D

Until last year, BioAge Labs' progress could be best described as a slow burn, with a pipeline of longevity-focused medicines taking shape incrementally but consistently. The frenzy around GLP-1s changed all of that, with BioAge’s profile ascending dramatically thanks to being one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. Equipped with that potential, and a partnership with Eli Lilly to test the hypothesis, BioAge has closed a $170 million series D led by Sofinnova with contributions from major institutional biotech investors and the venture arms of both the Indianapolis pharma and Amgen.

Eli Lilly partner BioAge raises $170 mln for obesity treatment

BioAge Labs, a biotech startup collaborating with Eli Lilly (LLY.N), opens new tab for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.
Browse Insights
Other Companies Like BioAge in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
ArsenalBioArsenalBio----$xx.xxSeries C$1.66B$xx.xx$327.5MM
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
EgenesisEgenesis----$xx.xxSeries D$332.59MM$xx.xx$90.96MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
OwkinOwkin----$xx.xxSeries B-1$1.46B$xx.xx$50MM
Precision NeurosciencePrecision Neuroscience----$xx.xxSeries C$542.69MM$xx.xx$102MM
Xaira TherapeuticsXaira Therapeutics----$xx.xxSeries A$2.65B$xx.xx$500MM

Updated on: Jan 17, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.